

Meril

Cardiovascular

Evermine50™

— EES-KLES Study —

Clinical outcomes of ultrathin strut biodegradable polymer-coated everolimus-eluting stent in patients with coronary artery disease

Evermine50 EES-KLES Study Design

SINGLE-ARM, ALL-COMERS AND SINGLE-CENTER STUDY

- Between April 2016 and December 2016 this retrospective study enrolled 171 patients (258 lesions) implanted with Evermine50 EES for managing CAD at a single centre in India
- **Inclusion Criteria:** All-comer patients aged > 18 years with CAD
- Patients (mean age: 57.85 ± 10.05 years, 81.29% male) treated for CAD with Evermine50 EES included:
  - DM - 40.9%
  - HTN - 40.3%
  - STEMI - 43.8%
  - UA - 24.5%
- **Primary Endpoints:** MACE, was defined as a composite of cardiac death, MI, and ID-TLR at 6-, 12-, and 24-month follow-up
- **Additional Endpoints:** Procedural success was defined as technical success with no MACE noted within 24 hours of the index procedure

PRIMARY ENDPOINT

Evermine50 EES demonstrated a 2.42% MACE rate at 2-year in an all comer CAD population

The cumulative MACE-free survival, determined by the Kaplan–Meier method, was 97.66%



EES = Everolimus eluting stent, CAD= Coronary artery disease, DM = Diabetic mellitus, HTN = Hypertension, STEMI = Segment elevation myocardial infarction, UA = Unstable angina, MACE = Major adverse cardiovascular events, MI = Myocardial infarction, ID -TLR = Ischemia driven target lesion revascularization

Clinical Outcomes

KEY CLINICAL ENDPOINTS AT 2-YEAR:



MACE RATE:

KEY OUTCOMES:



At the 24-month follow-up, the results depict, the favorable safety and performance of the world's thinnest strut biodegradable polymer Evermine50 EES

SCAN ME

Or

CLICK HERE

For the full article

ID - TVR = Ischemia driven target vessel revascularization, ST = Stent thrombosis

CTRI/2017/09/009939